Development of bispecific T cell engagers: harnessing quantitative systems pharmacology
Trends in Pharmacological Sciences · 2023-12 · 44 (12) · 880-890
DOI: 10.1016/j.tips.2023.09.009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Pharmacological Sciences, 2023-12. Verfasst von Timothy Qi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill,…. Hauptthemen laut MEDLINE: Pharmacology, Antibodies, Bispecific. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences, National Institutes of Health.
Abstract (Originalsprache)
Bispecific T cell engagers (bsTCEs) have emerged as a promising class of cancer immunotherapy. Several bsTCEs have achieved marketing approval; dozens more are under clinical investigation. However, the clinical development of bsTCEs remains rife with challenges, including nuanced pharmacology, limited translatability of preclinical findings, frequent on-target toxicity, and convoluted dosing regimens. In this opinion article we present a distinct perspective on how quantitative systems pharmacology (QSP) can serve as a powerful tool for overcoming these obstacles. Recent advances in QSP modeling have empowered developers of bsTCEs to gain a deeper understanding of their context-dependent pharmacology, bridge gaps in experimental data, guide first-in-human (FIH) dose selection, design dosing regimens with expanded therapeutic windows, and improve long-term treatment outcomes. We use recent case studies to exemplify the potential of QSP techniques to support future bsTCE development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, The University…
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
- National Institutes of Health
Zitieren
APA
Qi, T., Liao, X., & Cao, Y. (2023). Development of bispecific T cell engagers: harnessing quantitative systems pharmacology. Trends in Pharmacological Sciences, 44(12), 880-890. https://doi.org/10.1016/j.tips.2023.09.009
Vancouver
Qi T, Liao X, Cao Y. Development of bispecific T cell engagers: harnessing quantitative systems pharmacology. Trends in Pharmacological Sciences. 2023;44(12):880-890. doi:10.1016/j.tips.2023.09.009
BibTeX
@article{Qi2023,
author = {Qi, Timothy and Liao, Xiaozhi and Cao, Yanguang},
title = {Development of bispecific T cell engagers: harnessing quantitative systems pharmacology},
journal = {Trends in Pharmacological Sciences},
year = {2023},
volume = {44},
number = {12},
pages = {880--890},
doi = {10.1016/j.tips.2023.09.009}
}
EUVIMED